Coiling of Large and Giant Aneurysms: Complications and Long-Term Results of 334 Cases

N. Chalouhi, S. Tjoumakaris, L.F. Gonzalez, A.S. Dumont, R.M. Starke, D. Hasan, C. Wu, S. Singhal, L.A. Moukarzel, R. Rosenwasser, and P. Jabbour

ABSTRACT

BACKGROUND AND PURPOSE: Large and giant intracranial aneurysms are increasingly treated with endovascular techniques. The goal of this study was to retrospectively analyze the complications and long-term results of coiling in large and giant aneurysms (≥ 10 mm) and identify predictors of outcome.

MATERIALS AND METHODS: A total of 334 large or giant aneurysms (≥ 10 mm) were coiled in our institution between 2004 and 2011. Medical charts and imaging studies were reviewed to determine baseline characteristics, procedural complications, and clinical/angiographic outcomes. Aneurysm size was 15 mm on average. Two hundred twenty-five aneurysms were treated with conventional coiling; 88, with stent-assisted coiling; 14, with parent vessel occlusion; and 7, with balloon-assisted coiling.

RESULTS: Complications occurred in 10.5% of patients, with 1 death (0.3%). Aneurysm location and ruptured aneurysms predicted complications. Angiographic follow-up was available for 84% of patients at 25.4 months on average. Recanalization and retreatment rates were 39% and 33%, respectively. Larger aneurysm size, increasing follow-up time, conventional coiling, and aneurysm location predicted both recurrence and retreatment. The annual rebleeding rate was 1.9%. Larger aneurysm size, increasing follow-up time, and aneurysm location predicted new or recurrent hemorrhage. Favorable outcomes occurred in 92% of patients. Larger aneurysm size, poor Hunt and Hess grades, and new or recurrent hemorrhage predicted poor outcome.

CONCLUSIONS: Coiling of large and giant aneurysms has a reasonable safety profile with good clinical outcomes, but aneurysm reopening remains very common. Stent-assisted coiling has lower recurrence, retreatment, and new or recurrent hemorrhage rates with no additional morbidity compared with conventional coiling. Aneurysm size was a major determinant of recanalization, retreatment, new or recurrent hemorrhage, and poor outcome.

ABBREVIATIONS: GOS = Glasgow Outcome Score; PED = Pipeline Embolization Device

Large and giant intracranial aneurysms (≥ 10 mm) have a poor natural history and usually warrant intervention. A recently published study from Japan reported an annual rupture rate of 4.37% for 10- to 24-mm aneurysms and 33.4% for aneurysms larger than 24 mm.¹ Treatment options for large and giant aneurysms include open surgery or endovascular techniques. Surgical treatment is often challenging and can be associated with significant morbidity.^{2,3} Endovascular therapy has emerged as a minimally in-

vasive alternative to open surgery in most neurovascular centers.^{4,5} Available endovascular modalities include endosaccular coiling with or without stent/balloon assistance, endovascular parent vessel deconstruction, Onyx HD-500 (ev3, Irvine, California) embolization, and, recently, flow diversion.⁶ Endosaccular coiling is currently the most commonly used treatment technique for large and giant aneurysms, especially in the setting of subarachnoid hemorrhage. Parent vessel occlusion, when tolerated, is also a reliable and durable treatment typically considered in giant aneurysms.⁴

Despite increasing and widespread use of endovascular techniques, little is known about the morbidity rates, rehemorrhage rates, and long-term angiographic results of coiling in large and giant aneurysms. In addition, predictors of treatment outcome have not been identified. In this study, we analyzed the complications and long-term results of coiling in the largest series of large and giant aneurysms (≥ 10 mm) to date. In addition, a multivariate logistic regression analysis was conducted to identify predictors of complications,

Received April 29, 2013; accepted after revision May 28.

From the Department of Neurosurgery (N.C., S.T., L.F.G., A.S.D., R.M.S., C.W., S.S., L.A.M., R.R., P.J.), Thomas Jefferson University and Jefferson Hospital for Neuroscience, Philadelphia, Pennsylvania; and Department of Neurosurgery (D.H.), University of Iowa, Iowa City, Iowa.

Please address correspondence to Pascal M. Jabbour, MD, Department of Neurosurgery, Division of Neurovascular Surgery and Endovascular Neurosurgery, Thomas Jefferson University Hospital, 901 Walnut St, 3rd Floor, Philadelphia, PA 19107; e-mail: pascal.jabbour@jefferson.edu

<http://dx.doi.org/10.3174/ajnr.A3696>

recurrence, retreatment, new or recurrent hemorrhage, and clinical outcome.

MATERIALS AND METHODS

Study Design, Participants, and Setting

The university institutional review board approved the study protocol. We searched our prospectively maintained data base for all patients with large or giant aneurysms (>10 mm) who were treated with primary coil embolization in our institution between May 2004 and May 2011. A total of 324 consecutive patients with 334 aneurysms met the study criteria and constituted our study population. During the same time, 139 large or giant aneurysms were clipped at our institution; these patients were not included in the analysis. The decision to treat aneurysms with endovascular therapy was based on patient preferences, aneurysm morphology, aneurysm–parent vessel relationship, and comorbidities that rendered a patient a poor surgical candidate.

Medical charts and imaging studies were reviewed to determine patient age, sex, aneurysm size, aneurysm location, aneurysm morphology, Hunt and Hess grade, procedural specifics, procedural morbidity and mortality, immediate and follow-up angiographic results, need for retreatment, morbidity associated with recoiling, angiographic outcome of recoiling, new or recurrent hemorrhage, and clinical outcome. Treatment failure was defined as an inability to place coils into an aneurysm. Procedure-related complications (ischemia, hemorrhage, dissections, new cranial nerve deficits) were reported regardless of their clinical significance. Thromboembolic complications were diagnosed intraoperatively on digital subtraction angiography, clinically as new deficits or change in the level of consciousness, or on CT/MR imaging (new infarcts) performed in cases of sudden neurologic compromise. Ischemic/thromboembolic complications were also recorded through follow-up. Radiographic follow-up (DSA or MR) was scheduled at 6 months, 1 year, 2 years, and 5 years after endovascular procedures. Initial aneurysm occlusion was determined as a percentage occlusion rate. Initial and follow-up angiographic images were compared to determine the rate of aneurysm recanalization. Any aneurysm that displayed a recurrence of $\geq 5\%$ on follow-up angiography was considered recurrent. Clinical outcomes were retrospectively collected at discharge and at follow-up from follow-up notes of the attending physician and classified by using the Glasgow Outcome Score (GOS) as follows: I, deceased; II, vegetative state; III, severely disabled; IV, moderately disabled; and V, mildly or not disabled.

Aneurysm Coiling

The decision to treat aneurysms with endovascular therapy was based on patient preferences, aneurysm morphology, aneurysm–parent vessel relationship, and comorbidities that rendered a patient a poor surgical candidate. In aneurysms with a favorable geometry, the aim of treatment was selective and complete coiling of the aneurysm with preservation of the patency of the parent artery. Depending on operator preferences, wide-neck aneurysms were coiled either with stent assistance by using Neuroform (Stryker Neurovascular, Fremont, California) and Enterprise (Codman & Shurtleff, Raynham, Massachusetts) stents or with balloon assistance by using the HyperGlide or HyperForm balloon (ev3). For unruptured aneurysms, endosaccular coiling was performed with an initial 100 U/Kg of heparin bolus and mainte-

nance of activated clotting time of 2 times the patient's baseline intraoperatively. Coils (bare platinum) were placed until satisfactory aneurysm obliteration was achieved and/or placement of additional coils was not possible. Patients in whom the use of a stent was anticipated were pretreated with 81 mg of aspirin and 75 mg of clopidogrel 10 days before the procedure. For stent-assisted procedures performed in the setting of a subarachnoid hemorrhage, patients were loaded with 600 mg of clopidogrel intraprocedurally and a 50-U/kg heparin bolus after deployment of the first coil. Patients were then maintained on daily doses of 75 mg of clopidogrel and 81 mg of aspirin for 2 months, followed by aspirin, 81 mg daily, indefinitely. Because several operators performed the procedures, the protocols and techniques may have varied to some extent.

Parent Vessel Occlusion

Parent vessel occlusion was typically considered in giant and/or fusiform aneurysms of the internal carotid artery. Patient tolerance for permanent vessel occlusion was first assessed with a balloon test occlusion. Briefly, a balloon was advanced over a microguidewire and slowly inflated at the planned occlusion site. Complete balloon occlusion of the parent vessel was verified by proximal contrast injection. The awake patient was then monitored for 30 minutes with continuous clinical examination. The test was performed under normotensive parameters for the first 15 minutes followed by a hypotensive challenge for the remaining 15 minutes. The extent of intracranial collateral circulation was concurrently examined by angiography. The balloon test occlusion was "passed" by patients who remained neurologically intact during the test. The balloon was kept inflated, and flow arrest was confirmed angiographically. Vessel occlusion was then achieved with coils alone or with a combination of Onyx and coils. In the latter case, a few coils were initially deployed in the vessel through the inflated balloon or a separate microcatheter to create a framework for subsequent Onyx injection. Patients were closely monitored in the neurointensive care unit. All patients, including those who had experienced a subarachnoid hemorrhage, were prescribed maintenance antiplatelet therapy (usually daily aspirin).

Statistical Analysis

Data are presented as mean and range for continuous variables and as frequency for categorical variables. Analysis was carried out by using an unpaired *t* test, χ^2 test, Fisher exact test, and analysis of variance as appropriate. Univariate analysis was used to test covariates predictive of dependent variables: procedural complications, aneurysm recanalization, aneurysm retreatment, new or recurrent hemorrhage, and patient outcome (GOS IV-V versus I-II-III). Interaction and confounding were assessed through stratification and relevant expansion covariates. Factors predictive in univariate analysis ($P < .15$)⁷ were entered into a multivariate logistic regression analysis. *P* values $\leq .05$ were considered statistically significant. Statistical analysis was performed with STATA 10.0 (StataCorp, College Station, Texas).

RESULTS

A total of 324 patients with 334 large or giant aneurysms underwent coiling at our institution. Mean age was 57 years (range, 15–89 years). Seventy-seven percent of patients ($n = 250$) were

Table 1: Location of treated aneurysms and respective complication and recurrence rates

Location	No. of Aneurysms (%)	Complications (%)	Recurrence (%)	Retreatment (%)
Paraclinoid	63 (18.9)	9 (14.3)	26/53 (49)	22/53 (41.5)
Basilar artery	53 (15.9)	4 (7.5)	16/43 (37.2)	15/43 (34.9)
Posterior communicating artery	48 (14.4)	6 (12.5)	11/33 (33.3)	10/33 (30.3)
Carotid ophthalmic	47 (14.1)	3 (6.4)	12/39 (30.8)	10/39 (25.6)
Anterior communicating artery	34 (10.2)	5 (14.7)	6/25 (24)	5/25 (20)
Carotid cavernous	27 (8.0)	4 (14.8)	9/21 (42.9)	6/21 (28.6)
Middle cerebral artery	25 (7.5)	2 (8)	8/16 (50)	5/16 (31.3)
Carotid terminus	17 (5.1)	0	5/11 (45.5)	4/11 (36.4)
Vertebral artery	13 (3.9)	1 (7.7)	5/12 (41.7)	5/12 (41.7)
Anterior cerebral artery	6 (1.8)	0	4/6 (66.7)	4/6 (66.7)
Posterior cerebral artery	1 (0.3)	0	0/1	0/1
Total	334	34	102	85

female. Aneurysm size was 15 mm on average (range, 10–45 mm). Of 334 aneurysms, 216 (64%) were between 10 and 14 mm, 86 (26%) were between 15 and 24 mm, and 32 (10%) were ≥ 25 mm. Aneurysm locations are summarized in Table 1. Eighty percent of aneurysms ($n = 268$) were located in the anterior circulation (including posterior communicating artery aneurysms). Fourteen aneurysms (4.1%) had a fusiform morphology. Hunt and Hess grades were zero in 175 (54%) patients, I in 32 (10%) patients, II in 16 (4.9%) patients, III in 63 (19.4%) patients, IV in 34 (10.5%) patients, and V in 4 (1.2%) patients.

Initial Treatment

Of 334 aneurysms, 14 (2.4%) were initially treated with parent vessel occlusion, and 320 (97.6%), with endosaccular coiling. Parent vessel occlusion was performed with coils alone in 5 patients and with a combination of Onyx and coils in 9 patients. Among the other 320 aneurysms, 7 (2.2%) were treated with balloon-assisted coiling; 88 (27.5%), with stent-assisted coiling; and 225 (70.3%), with unassisted coiling. Three patients (0.9%) had an unsuccessful procedure and underwent surgical clipping. Seventeen patients were stent-coiled in the acute setting of subarachnoid hemorrhage.

Complications related to the initial procedure occurred in 34 (10.5%) patients, resulting in 1 death (0.3%). Seventeen patients died during initial hospitalization from causes unrelated to aneurysm embolization. Complications were as follows: 31 (9.6%) thromboembolic or ischemic events (including 3 clinically silent infarcts), 2 (0.6%) intraprocedural aneurysm ruptures, and 1 (0.3%) cranial nerve palsy. Specifically, procedural complications occurred in 22 (9.8%) patients treated with unassisted coiling, 10 (11.4%) patients treated with stent-assisted coiling, and 2 (14.3%) patients treated with parent vessel occlusion ($P = .7$). The complication rate was 7.4% ($n = 13$) for patients with unruptured aneurysms and 14% ($n = 21$) for those with ruptured aneurysms ($P = .05$). Complication rates were 10.2% ($n = 22$) for aneurysms between 10 and 14 mm, 10.4% ($n = 9$) for aneurysms between 15 and 24 mm, and 9.4% ($n = 3$) for aneurysms of ≥ 25 mm ($P = .8$).

Table 1 summarizes complication rates per aneurysm location. Patients who were stented in the acute setting of hemorrhage did not have any hemorrhagic complications. In multivariate analysis, carotid cavernous–paraclinoid–anterior communicating artery aneurysms (OR = 2.1; 95% CI, 1.1–3.9; $P = .02$) and

Table 2: Complications and angiographic outcomes per aneurysm size

	10–14 mm	15–24 mm	≥ 25 mm
Complications	22/216 (10.2%)	9/86 (10.4%)	3/32 (9.4%)
Recurrence	62/177 (35%)	29/62 (46.8%)	11/21 (52%)
Retreatment	52/177 (29.3%)	23/62 (37.1%)	10/21 (47.6%)

ruptured aneurysms (OR = 2.4; 95% CI, 1.1–4.3; $P = .04$) were predictive of complications. There was also a trend toward anterior circulation-versus-posterior circulation aneurysms (OR = 2; 95% CI, 0.9–5.0; $P = .09$) to predict complications. The type of treatment and aneurysm size were not predictive factors.

Immediate occlusion ($\geq 95\%$) was achieved in 290 (87.6%) aneurysms. Excluding the 3 patients with a failed procedure and the 18 patients who died during initial hospitalization, angiographic follow-up was available for 85% of patients (260/303) at a mean of 25.4 months. Of 260 aneurysms, 102 (39%) showed recanalization at follow-up and 85 (33%) required further treatment. Initial retreatment consisted of additional coiling in 51 aneurysms, balloon-assisted coiling in 2, stent-assisted coiling in 19, Onyx HD 500 embolization in 2, Pipeline Embolization Device (PED) therapy in 2, parent vessel occlusion in 3, and microsurgical clipping in 6. Recurrence and retreatment rates (Table 2) were, respectively, 35% (62/177) and 29.3% (52/177) for aneurysms between 10 and 14 mm, 46.8% (29/62) and 37.1% (23/62) for aneurysms between 15 and 24 mm, and 52% (11/21) and 47.6% (10/21) for aneurysms ≥ 25 mm ($P = .005$, $P = .003$). Recurrence and retreatment rates were, respectively, 44% (72/164) and 37.2% (61/164) for unassisted coiling, 32.5% (26/80) and 26% (21/80) for stent-assisted coiling, 40% (2/5) and 40% (2/5) for balloon-assisted coiling, and 18.2% (2/11) and 9.1% (1/11) for parent vessel occlusion ($P = .03$, $P = .02$). Table 1 summarizes recanalization and recurrence rates per aneurysm location. In multivariate analysis, larger aneurysm size, increasing follow-up time, unassisted coiling and balloon-assisted coiling versus stent-assisted coiling or parent vessel occlusion, and carotid cavernous–paraclinoid–anterior cerebral artery–vertebral artery–carotid terminus–middle cerebral artery aneurysms were independent predictors of both recurrence and retreatment (Table 3).

At discharge, 89% ($n = 286$) of patients attained a favorable outcome (GOS IV–V) (Table 4). Specifically, a favorable outcome was noted in 98% ($n = 172$) of patients with unruptured aneurysms and 77% ($n = 114$) of patients with ruptured aneurysms.

Table 3: Predictors of recurrence and retreatment

	Odds Ratio	95% CI	P Value
Procedural complications			
Ruptured aneurysms	2.4	1.1–4.3	.04 ^a
Aneurysm location	2.1	1.1–3.9	.02 ^a
Anterior circulation aneurysms	2.0	0.9–5.0	.09
Recurrence			
Aneurysm size	1.07	1.02–1.14	.006 ^a
Follow-up time	1.04	1.02–1.06	<.001 ^a
Unassisted coiling and balloon remodeling	2	1.1–3.3	.02 ^a
Aneurysm location	1.9	1.1–3.4	.02 ^a
Retreatment			
Aneurysm size	1.08	1.02–1.14	.003 ^a
Follow-up time	1.02	1.02–1.06	.002 ^a
Unassisted coiling and balloon remodeling	2.5	1.1–3.3	.005 ^a
Aneurysm location	2.02	1.1–3.4	.02 ^a
New or recurrent hemorrhage			
Aneurysm size	1.1	1.0–1.2	.04 ^a
Follow-up time	1.03	1.0–1.1	.05 ^a
Aneurysm location	2.5	1.5–7	.01 ^a
Clinical outcome			
Aneurysm size	0.89	0.82–0.97	.01 ^a
Hunt and Hess grades	0.36	0.24–0.55	<.001 ^a
New or recurrent hemorrhage	0.04	0.005–0.28	.002 ^a

^a Statistically significant values. Factors tested as predictors of complications: age, sex, embolization, initial aneurysm occlusion, and date of treatment. Factors tested as predictors of recurrence, retreatment, and new or recurrent hemorrhage: age, sex, aneurysm size, location, ruptured aneurysm status, Hunt and Hess grades, type of embolization, initial aneurysm occlusion, date of treatment, procedural complications, GOS at discharge, and follow-up time. Factors tested as predictors of clinical outcome: age, sex, aneurysm size, location, ruptured aneurysm status, Hunt and Hess grades, type of embolization, initial aneurysm occlusion, date of treatment, procedural complications, GOS at discharge, follow-up time, recurrence, retreatment, and new or recurrent hemorrhage.

Table 4: Clinical outcome of treated patients

GOS	Discharge (%)	Follow-Up (%)
I, Death	17 (5.3)	7 (2.7)
II, Vegetative state	1 (0.3)	1 (0.4)
III, Severe disability	18 (5.6)	12 (4.7)
IV, Moderate disability	21 (6.5)	17 (6.6)
V, Mild/no disability	265 (82.3)	219 (85.6)

Aneurysm Recoiling: Morbidity and Angiographic Outcome

Angiographic follow-up was available for 55 of the 75 aneurysms that were recoiled (including stent/balloon-assisted coiling and parent vessel occlusion). Among these 55 aneurysms, 30 (54.5%) showed another recurrence at follow-up. Specifically, a recurrence was noted in 37.5% (6/16) of aneurysms retreated with stent-assisted coiling versus 61.5% (24/39) of those recoiled without stent assistance ($P = .1$).

Of the 30 aneurysms that showed a second recurrence after coiling, 24 (43.6%) required retreatment, including recoiling in 19 aneurysms. Angiographic follow-up was available for 15 of these 19 aneurysms, and a third recurrence was noted in 8 of these 15 aneurysms (53.3%), requiring further treatment in 6 (40%).

Complications were noted in 5 of the 75 patients (6.6%) whose aneurysms required further coiling. The rate of complications per recoiling procedure was 5% (5/100).

New or Recurrent Hemorrhage and Long-Term Clinical Outcome

Eleven patients (4.2%, $n = 256$) had a new or recurrent subarachnoid hemorrhage at a median of 12 months (range, 1 week to 7 years) following successful aneurysm treatment. The annual rate

of new or recurrent hemorrhage was 1.9% (11 hemorrhages in 564 years of follow-up). Seven of these patients had aneurysm occlusion of $\geq 95\%$ after initial embolization. Four hemorrhages occurred within 2 months of treatment. Five of these patients died, and 3 remained severely disabled at follow-up. Mean aneurysm size was 17 mm in this group. Ten patients had been initially treated with conventional coiling, and only 1, with stent-assisted coiling. Thus, the rate of new or recurrent hemorrhage was 6.0% for conventional coiling versus 1.3% for stent-assisted coiling ($P = .1$). In multivariate analysis, larger aneurysm size (> 15 mm) (OR = 1.1; 95% CI, 1.0–1.2; $P = .04$), increasing follow-up time (OR = 1.03; 95% CI, 1.0–1.1; $P = .05$), and basilar tip–anterior communicating–posterior communicating aneurysm locations (OR = 2.5; 95% CI, 1.5–7; $P = .01$) were independent predictors of new or recurrent hemorrhage. The type of initial aneurysm treatment fell short of statistical significance.

Clinical follow-up was available for 85% of patients ($n = 256$) at a mean of 26.3 months, excluding patients with a failed procedure and those who died during the initial hospitalization. A favorable outcome (GOS IV–V) was attained by 92% ($n = 236$) of patients at follow-up. Specifically, 87% (93/107) of patients with ruptured aneurysms and 96% (143/149) of patients with unruptured aneurysms achieved a favorable outcome (GOS IV–V). In multivariate analysis, increasing aneurysm size (OR = 0.89; 95% CI, 0.82–0.97; $P = .01$), poor Hunt and Hess grades (OR = 0.36; 95% CI, 0.24–0.55; $P < .001$), and new or recurrent hemorrhage (OR = 0.04; 95% CI, 0.005–0.28; $P = .002$) were negative independent predictors of favorable outcome (GOS IV–V).

DISCUSSION

In this study, we have reviewed our experience with coil embolization of large and giant aneurysms (≥ 10 mm) and identified several independent predictors of treatment outcome. This report may serve as a reference for comparison with other treatment options for this category of aneurysm, namely flow diversion and surgical clipping. Our study has also afforded an opportunity to compare different endovascular techniques in terms of complications and angiographic outcome.

Coil embolization remains the most commonly used endovascular technique for securing large and giant aneurysms. Complications occurred in 10.5% of patients in our series, but many were clinically silent or minor events. The procedural mortality rate was minimal (0.3%), and the rate of favorable outcome at clinical follow-up (92%) was high. Unfortunately, to our knowledge, there are no reports in the literature pertaining specifically to large and giant aneurysms (> 10 mm) with which to compare

our findings. In a systematic review of giant aneurysms (≥ 25 mm) treated with conventional endovascular approaches, the rates of morbidity and mortality were 17% and 8%, respectively.⁸ Gruber et al⁹ treated 31 very large and giant aneurysms (> 20 mm) with endosaccular coiling with a 13.3% procedure-related morbidity rate and a 6.7% procedure-related mortality rate and reported favorable outcomes in 73.3% of patients. Likewise, Sluzewski et al¹⁰ achieved a good clinical outcome in nearly 80% of patients with very large and giant aneurysms (> 20 mm) treated with coiling. The higher rate of favorable outcomes in our study likely reflects the inclusion of smaller aneurysms (10–20 mm) in the analysis. In fact, increasing aneurysm size was independently predictive of poor outcome, recanalization, retreatment, and new or recurrent hemorrhage in multivariate analysis. Overall, coiling of large and giant aneurysms (≥ 10 mm) in our experience was associated with a reasonable safety profile and good clinical outcomes. Patients with larger aneurysms, however, are at higher risk of poor outcome.

The present study demonstrates high rates of recurrence (39%) and retreatment (33%) for large and giant aneurysms treated with coiling. Moreover, the risk of aneurysm recurrence was 54.5% after the first recoiling and 53.3% after the second recoiling. Aneurysm reopening remains, therefore, the major shortcoming of coiling (and repeat coiling) in large and giant aneurysms. This has been attributed to thrombus resolution, coil migration into the thrombus mass, and suboptimal packing of these aneurysms.¹⁰ Our results are remarkably similar to those of Murayama et al,¹¹ who reported, in 2003, their 11-year experience with aneurysm embolization. The recanalization rate was 35.3% for large aneurysms in their study and 59.1% for giant aneurysms. The lack of improvement relative to this prior series published 10 years ago suggests that further improvement in occlusion/recanalization rates for large aneurysms may well require adjunctive therapy. The fact that stent-assisted coiling was associated with lower recurrence rates in multivariate analysis compared with conventional coiling (with or without balloon assistance) is a crucial finding of our study. In addition, the risk of a second aneurysm recurrence was lower when recoiling was performed with-versus-without stent assistance (37.5% versus 61.5%). Moreover, there was a lower incidence of new or recurrent hemorrhage in patients treated with stent-assisted coiling versus conventional coiling (1.1% versus 4.7%).

Several reasons may account for the improved durability of treatment with self-expanding stents, including denser aneurysm packing with increased neck coverage, flow diversion, parent vessel straightening, and fibroelastic tissue formation along the neck of the aneurysm.^{12–16} Most important, the lower recurrence and rebleeding rates with stent-assisted techniques did not occur at the expense of an increased rate of complications. Previously, Piotin et al¹⁷ reported permanent neurologic deficit and mortality rates as high as 7.4% and 4.6%, respectively, with stent-assisted coiling compared with 3.8% and 1.2% with conventional coiling. Our study emphasizes the safety and efficacy of stent-assisted coiling and suggests that it may be the preferred treatment technique over conventional coiling for large and giant aneurysms.

The annual rebleeding rate was 1.9% in our study, exceeding the rate reported in the endovascular arm of the International

Subarachnoid Aneurysm Trial.¹⁸ This is expected given that 92% of coiled aneurysms in this trial were ≤ 10 mm. Rebleeding occurred both early and late after initial coiling and was independently predictive of poor clinical outcome. Larger aneurysms (> 15 mm) and basilar tip, anterior communicating, and posterior communicating aneurysms were strong predictors of rebleeding. Thus, patients with these risk factors should be very carefully followed and retreated, preferentially with stent-assisted techniques, in the event of aneurysm reopening to prevent rehemorrhage.

Recoiling in the present study was associated with a relatively low complication rate (5%) and no mortality. Previous studies have reported similarly low morbidity rates with recoiling. A multicenter study of 100 aneurysms requiring additional coiling because of an enlarging remnant and subtotal occlusion reported minor permanent neurologic deficits in only 3% of cases.¹⁹ Likewise, Kang et al²⁰ and Slob et al²¹ observed no complications during repeat embolization of recurrent aneurysms and suggested that procedural morbidity for retreatment may be lower than that for initial coiling.

The rate of complications for unruptured large and giant aneurysms in our study was low (7.4%), and excellent outcomes were achieved in this group. The best endovascular technique for these aneurysms (ie, coiling versus flow diversion), however, is not clear. In a small series of 42 patients, Lanzino et al²² reported similar rates of morbidity and a higher rate of complete angiographic obliteration with the PED (mean aneurysm size, 14.9 mm) compared with standard endovascular techniques (mean aneurysm size, 13.9 mm). The authors concluded that careful long-term follow-up was important to definitively validate flow diversion as a superior treatment for proximal internal carotid artery aneurysms. Elsewhere, flow diversion was associated with significant procedural risks. A recent systematic review on unruptured aneurysms treated with endovascular techniques found that flow diversion was associated with significantly higher risks compared with other endovascular techniques.²³ The risk of major stroke or neurologic death was 5.6% in the Pipeline for Uncoilable or Failed Aneurysms trial²⁴ (mean aneurysm size, 14.6 mm) and 8.5% (including 4 fatal postprocedural hemorrhages) in a recent multicenter study from 7 American neurosurgical centers (proportion of aneurysms larger than 7 mm, 83%).²⁵ In the Canadian experience (mean aneurysm size, 19 mm), the overall morbidity and mortality rate associated with PED treatment was 10.7% (6.3% mortality, 4.4% morbidity).²⁶

These data suggest that the risk associated with flow diversion is not insignificant and that further study is needed to elucidate the best treatment option for unruptured large and giant aneurysms. On the other hand, for patients with acutely ruptured aneurysms, flow diversion is barely an option and almost all aneurysms are either coiled or clipped. McAuliffe and Wenderoth²⁷ treated 11 patients with recently ruptured aneurysms by using the PED and reported 2 deaths during the acute illness due to aneurysm rebleeding (18%). The authors recommended that the device be used as a coil scaffold rather than a flow diverter. In the posterior circulation as well, flow diversion is generally used very cautiously because it is associated with significant morbidity and high rates of perforator infarcts.^{25,28,29} Conversely, in the present

study, there was a trend toward lower complication rates with coiling in the posterior circulation. Thus, coiling remains the preferred option for ruptured aneurysms and posterior circulation aneurysms.

Parent vessel occlusion is widely used in the management of giant intracranial aneurysms. The complication rate in the present series (14.3%) was within the range reported in the literature,^{16,30–33} and aneurysm reopening was somewhat uncommon. The advantage of the technique is that it excludes the aneurysm definitely from the circulation and may not require follow-up imaging.⁴ In contrast to flow diverters and endosaccular coiling, there is practically no risk of delayed aneurysm rupture after parent vessel occlusion. For some authors, parent vessel occlusion is the safest and most effective treatment for large and giant aneurysms and remains the first-line option in this setting.³⁴ The main disadvantage of parent vessel occlusion is the risk of development of postoperative stroke. Therefore, it is important to perform a balloon test occlusion to determine patient tolerance for permanent arterial occlusion because the incidence of postoperative stroke is substantially higher without previous tolerance testing.^{35–37} Also, in the setting of subarachnoid hemorrhage, parent vessel occlusion is generally avoided due to potential aggravation of ischemic complications of vasospasm.

This was a retrospective review of a single-center experience with coiling of large and giant aneurysms. There was no randomization of the different subgroups of the study. Comparison with other studies reporting on flow diversion or surgical clipping remains limited by inherent differences in methodology and design. In the future, it would be interesting to compare conventional endovascular techniques with flow diversion or surgical clipping to determine the best technique in this setting.

CONCLUSIONS

In this study, coiling of large and giant aneurysms was associated with a reasonable safety profile and good clinical outcome. Aneurysm reopening, however, was very common after endosaccular coiling. Larger aneurysm size was independently predictive of recanalization, retreatment, new or recurrent hemorrhage, and poor outcome. Stent-assisted coiling was associated with lower recurrence, retreatment, and new or recurrent hemorrhage rates with no additional morbidity compared with conventional coiling. Thus, stent-assisted coiling should probably be considered the preferred treatment option over conventional coiling for large and giant aneurysms. The annual rebleeding rate was 1.9%, and larger aneurysms (>15 mm) and basilar tip, anterior communicating artery, and posterior communicating artery aneurysms were strong predictive factors. The major determinants of clinical outcome were aneurysm size, Hunt and Hess grades, and new or recurrent hemorrhage.

Disclosures: Stavropoulou Tjoumakaris—UNRELATED: Consultancy: Stryker. Aaron S. Dumont—UNRELATED: Consultancy: ev3. Pascal Jabbour—UNRELATED: Consultancy: ev3, CNV.

REFERENCES

- Morita A, Kirino T, Hashi K, et al. **The natural course of unruptured cerebral aneurysms in a Japanese cohort.** *N Engl J Med* 2012;366:2474–82
- Sundt TM Jr, Piepgras DG. **Surgical approach to giant intracranial aneurysms: operative experience with 80 cases.** *J Neurosurg* 1979;51:731–42
- Kalani MY, Zabramski JM, Hu YC, et al. **Extracranial-intracranial bypass and vessel occlusion for the treatment of unclippable giant middle cerebral artery aneurysms.** *Neurosurgery* 2013;72:428–35, discussion 435–36
- van Rooij WJ, Sluzewski M. **Endovascular treatment of large and giant aneurysms.** *AJNR Am J Neuroradiol* 2009;30:12–18
- Roy D, Milot G, Raymond J. **Endovascular treatment of unruptured aneurysms.** *Stroke* 2001;32:1998–2004
- Chalouhi N, Jabbour P, Singhal S, et al. **Stent-assisted coiling of intracranial aneurysms: predictors of complications, recanalization, and outcome in 508 cases.** *Stroke* 2013;44:1348–53
- Altman DG. *Practical Statistics for Medical Research.* Boca Raton, Florida: Chapman & Hall/CRC; 1999
- Parkinson RJ, Eddleman CS, Batjer HH, et al. **Giant intracranial aneurysms: endovascular challenges.** *Neurosurgery* 2008;62(6 suppl 3):1336–45
- Gruber A, Killer M, Bavinszki G, et al. **Clinical and angiographic results of endosaccular coiling treatment of giant and very large intracranial aneurysms: a 7-year, single-center experience.** *Neurosurgery* 1999;45:793–803, discussion 803–04
- Sluzewski M, Menovsky T, van Rooij WJ, et al. **Coiling of very large or giant cerebral aneurysms: long-term clinical and serial angiographic results.** *AJNR Am J Neuroradiol* 2003;24:257–62
- Murayama Y, Nien YL, Duckwiler G, et al. **Guglielmi detachable coil embolization of cerebral aneurysms: 11 years' experience.** *J Neurosurg* 2003;98:959–66
- Chalouhi N, Dumont AS, Hasan D, et al. **Is packing density important in stent-assisted coiling?** *Neurosurgery* 2012;71:381–86, discussion 386–87
- Chalouhi N, Drueding R, Starke RM, et al. **In-stent stenosis after stent-assisted coiling: incidence, predictors and clinical outcomes of 435 cases.** *Neurosurgery* 2013;72:390–96
- Chalouhi N, Jabbour P, Gonzalez LF, et al. **Safety and efficacy of endovascular treatment of basilar tip aneurysms by coiling with and without stent assistance: a review of 235 cases.** *Neurosurgery* 2012;71:785–94
- Jahshan S, Abla AA, Natarajan SK, et al. **Results of stent-assisted vs non-stent-assisted endovascular therapies in 489 cerebral aneurysms: single-center experience.** *Neurosurgery* 2013;72:232–39
- Chalouhi N, Starke RM, Koltz MT, et al. **Stent-assisted coiling versus balloon remodeling of wide-neck aneurysms: comparison of angiographic outcomes.** *AJNR Am J Neuroradiol* 2013;34:1987–92
- Piotin M, Blanc R, Spelle L, et al. **Stent-assisted coiling of intracranial aneurysms: clinical and angiographic results in 216 consecutive aneurysms.** *Stroke* 2010;41:110–15
- Molyneux AJ, Kerr RS, Birks J, et al. **Risk of recurrent subarachnoid haemorrhage, death, or dependence and standardised mortality ratios after clipping or coiling of an intracranial aneurysm in the International Subarachnoid Aneurysm Trial (ISAT): long-term follow-up.** *Lancet Neurol* 2009;8:427–33
- Renowden SA, Koumellis P, Benes V, et al. **Retreatment of previously embolized cerebral aneurysms: the risk of further coil embolization does not negate the advantage of the initial embolization.** *AJNR Am J Neuroradiol* 2008;29:1401–04
- Kang HS, Han MH, Kwon BJ, et al. **Repeat endovascular treatment in post-embolization recurrent intracranial aneurysms.** *Neurosurgery* 2006;58:60–70, discussion 60–70
- Slob MJ, Sluzewski M, van Rooij WJ, et al. **Additional coiling of previously coiled cerebral aneurysms: clinical and angiographic results.** *AJNR Am J Neuroradiol* 2004;25:1373–76
- Lanzino G, Crobeddu E, Cloft HJ, et al. **Efficacy and safety of flow diversion for paraclinoid aneurysms: a matched-pair analysis compared with standard endovascular approaches.** *AJNR Am J Neuroradiol* 2012;33:2158–61
- Naggara ON, Lecler A, Oppenheim C, et al. **Endovascular treatment**

- of intracranial unruptured aneurysms: a systematic review of the literature on safety with emphasis on subgroup analyses. *Radiology* 2012;263:828–35
24. Becske T, Kallmes DF, Saatci I, et al. Pipeline for uncoilable or failed aneurysms: results from a multicenter clinical trial. *Radiology* 2013;267:858–68
 25. Kan P, Siddiqui AH, Veznedaroglu E, et al. Early postmarket results after treatment of intracranial aneurysms with the Pipeline embolization device: a U.S. multicenter experience. *Neurosurgery* 2012;71:1080–88, discussion 1087–88
 26. O’Kelly CJ, Spears J, Chow M, et al. Canadian experience with the Pipeline embolization device for repair of unruptured intracranial aneurysms. *AJNR Am J Neuroradiol* 2013;34:381–87
 27. McAuliffe W, Wenderoth JD. Immediate and midterm results following treatment of recently ruptured intracranial aneurysms with the Pipeline embolization device. *AJNR Am J Neuroradiol* 2012;33:487–93
 28. Phillips TJ, Wenderoth JD, Phatouros CC, et al. Safety of the Pipeline embolization device in treatment of posterior circulation aneurysms. *AJNR Am J Neuroradiol* 2012;33:1225–31
 29. Chalouhi N, Tjoumakaris S, Dumont AS, et al. Treatment of posterior circulation aneurysms with the Pipeline embolization device. *Neurosurgery* 2013;72:883–89
 30. Barr JD, Lemley TJ. Endovascular arterial occlusion accomplished using microcoils deployed with and without proximal flow arrest: results in 19 patients. *AJNR Am J Neuroradiol* 1999;20:1452–56
 31. Graves VB, Perl J 2nd, Strother CM, et al. Endovascular occlusion of the carotid or vertebral artery with temporary proximal flow arrest and microcoils: clinical results. *AJNR Am J Neuroradiol* 1997;18:1201–06
 32. Larson JJ, Tew JM Jr, Tomsick TA, et al. Treatment of aneurysms of the internal carotid artery by intravascular balloon occlusion: long-term follow-up of 58 patients. *Neurosurgery* 1995;36:26–30, discussion 30
 33. Lewis AI, Tomsick TA, Tew JM Jr. Management of 100 consecutive direct carotid-cavernous fistulas: results of treatment with detachable balloons. *Neurosurgery* 1995;36:239–44, discussion 244–45
 34. van Rooij WJ, Sluzewski M, van der Laak C. Flow diverters for unruptured internal carotid artery aneurysms: dangerous and not yet an alternative for conventional endovascular techniques. *AJNR Am J Neuroradiol* 2013;34:3–4
 35. Serbinenko FA. Balloon catheterization and occlusion of major cerebral vessels. *J Neurosurg* 1974;41:125–45
 36. American Society of Interventional and Therapeutic Neuroradiology. Carotid artery balloon test occlusion. *AJNR Am J Neuroradiol* 2001;22(8 suppl):S8–9
 37. Sorteberg A, Bakke SJ, Boysen M, et al. Angiographic balloon test occlusion and therapeutic sacrifice of major arteries to the brain. *Neurosurgery* 2008;63:651–60, discussion 660–61